



医渡科技 12 月通讯 | 2023 年

Yidu Tech Events in December 2023

集团亮点

Business Update

医渡科技大模型正式发布，多项能力超越 GPT

Yidu Tech's Large Language Model Officially Released, Surpassing GPT in Multiple Capabilities

“2023 医疗智能大会”上，医渡科技自主研发的医疗垂域大模型正式发布，医渡科技医疗场景解决方案也随之迎来全面升级。目前医渡科技大模型在分导诊、基础医学、全科医学、临床内科、临床外科、执业医师考试等多个医疗明确任务场景上的评测表现已经超过 GPT3.5，并且已在多家全国排名前 20 的头部医院合作落地应用，同时正在“惠民保”领域先行试点。

At the "2023 Healthcare Intelligence Conference," Yidu Tech officially launched its proprietary large language model (LLM) in the medical vertical field, which also heralded a comprehensive upgrade to its medical scenario solutions. Currently, Yidu Tech's LLM has surpassed the performance of GPT-3.5 in various precise medical task scenarios such as hospital triage and guide, basic medicine, general medicine, clinical internal medicine, clinical surgery, and professional qualification exams. It has been implemented in collaboration with hospitals ranked among the national top 20 and is piloting in the "Hui Min Bao" field.



医渡科技与华为签署合作协议，发布智慧医疗联合解决方案

Yidu Tech and Huawei Signs Cooperation Agreement, Launches Joint Smart Healthcare Solutions

“2023 医疗智能大会”上，医渡科技与华为正式签署合作协议，并发布了聚焦医疗大模型、智慧医院、智慧健康城市三大场景的联合解决方案：医渡科技大模型训推一体机、科研大数据平台和智慧健康城市大数据平台。未来双方将开展技术研发、市场拓展、行业共建等全方位的战略生态合作，共同推动医疗大模型的创新与应用，加速医疗健康产业的智能化转型升级。

During the "2023 Healthcare Intelligence Conference," Yidu Tech and Huawei formally signed a cooperation agreement and released a joint solution focused on three major scenarios: LLM in the medical vertical field, smart hospitals, and smart health cities. The solutions include Yidu Tech's LLM training and inference integrated machine, a scientific research big data platform, and a smart health city big data platform. Both parties will engage in comprehensive strategic ecological cooperation in technology R&D, market expansion, and industry co-building to jointly promote the innovation and

application of large language models in the medical vertical field and accelerate the intelligent transformation and upgrading of the medical and health industry.



莆田市人民政府副市长胡国防一行莅临指导

Deputy Mayor of Putian City, Hu Guofang, and His Delegation Visits Yidu Tech for Inspection and Guidance

莆田市人民政府副市长、党组成员胡国防一行人莅临医渡科技视察指导，医渡科技首席执行官兼联合创始人徐济铭携公司管理团队亲切接待。胡国防副市长对于公司在医疗领域作出的贡献给予高度评价，认为公司在医疗行业数字化转型进程中的战略布局有宽度、产品研发有深度，企业文化有高度，不仅积极响应客户需求，还提供高效优质的服务，综合实力和竞争能力非常强，为医疗行业数字化转型做出了积极的贡献。

Hu Guofang, Deputy Mayor and Party Group Member of the Putian City People's Government, visited Yidu Tech for inspection and guidance. Xu Jiming, CEO and Co-founder of Yidu Tech, along with the company's management team, warmly received the delegation. Deputy Mayor Hu praised the company's contributions to the medical field and considered its strategic layout in the digital transformation of the medical industry to be broad, its product development deep, and its corporate culture lofty. He commended the company for not only actively responding to customer needs but also

providing efficient and high-quality services with solid comprehensive strength and competitive ability, greatly enhancing the digital transformation of the medical industry.



见证大流行病研究联盟正式成立，共同推动全球新发传染病研究协作

Inauguration of the Pandemic Research Alliance to Jointly Promote Global Collaboration in Emerging Infectious Disease Research

来自中国内地、香港以及海外共6间顶尖研究机构的传染病学教授在港举行联合记者会，宣布正式成立“大流行病学研究联盟”，医渡科技董事长兼创始人宫如璟女士与医渡科技 CEO、联合创始人徐济铭先生受邀出席，见证了这一全球联盟的成立。徐济铭表示，数据与算法的应用潜力巨大，能够在包括公共卫生在内的医疗健康领域发挥更为重要的作用，期待通过多方努力与合作，建立并完善更加牢固的公共卫生体系，使其更好的预测、防范，甚至避免下一次“大流行”。

Infectious disease professors from six leading research institutions across Mainland China, Hong Kong, and overseas held a joint press conference in Hong Kong to announce the formal establishment of the "Pandemic Research Alliance (PRA)". Ms. Gong Rujing, Chairlady and Founder of Yidu Tech, and Mr. Xu Jiming, CEO and Co-founder, were invited to witness this global alliance's inauguration. Xu Jiming stated

that the potential of data and algorithms is vast and can play an even more important role in medical and health fields, including public health. He looks forward to building and perfecting a more robust public health system through collaborative efforts, better predicting, preventing, and even avoiding the next "pandemic".



医渡科技徐济铭出席“京西健谈”第八届中国大健康产业升级峰会

Yidu Tech's Xu Jiming Attends the CHS 2023, 8th China Big Health Industry Upgrade Summit

“京西健谈”第八届中国大健康产业升级峰会在北京举办。医渡科技执行董事、CEO 兼联合创始人徐济铭受邀出席，并以《大模型时代的医疗生态体系构建》为题进行分享。徐济铭表示，医渡科技积极探索基于大模型产品的医疗多场景解决方案，将针对“医、教、研、管”提质增效，亦将直接为大众提供医学专业级别的个性化服务。

The 8th China Big Health Industry Upgrade Summit, CHS 2023, was held in Beijing. Xu Jiming, Executive Director, CEO, and Co-founder of Yidu Tech, was invited to attend and spoke on "Building a Medical Ecosystem in the Era of Large Language Models." Xu Jiming shared that Yidu Tech is actively exploring medical multi-scenario solutions based on large language model products, aiming to improve quality and efficiency in "healthcare services, education, research, and management," and directly provide the public with professional-level personalized medical services.



医渡科技闫峻出席 2023 未来医疗科技大会

Yidu Tech's Yan Jun Attends the 2023 Future Medical Technology Conference

2023 未来医疗科技大会在合肥成功举办。医渡科技 CTO、首席人工智能科学家闫峻博士受邀于“生成式 AI 场景论坛”发表主题演讲，分享了医疗垂域大模型的建设与应用。闫峻强调，技术应该从价值出发，否则即使技术再先进，缺乏实际价值也难以持续发展，“以价值创造为导向”也是医渡科技建设垂域大模型的基本理念。

The 2023 Future Medical Technology Conference was successfully held in Hefei. Dr. Yan Jun, CTO and Chief AI Scientist at Yidu Tech, was invited to deliver a keynote speech at the "Generative AI Forum," sharing the construction and application of large language model in the medical vertical field. Dr. Yan emphasized that technology should be value-driven; without practical value, even the most advanced technology cannot sustain development. Value-creation orientation is the fundamental philosophy behind Yidu Tech's development of LLM in the medical vertical field.



医渡科技亮相第九届浙江健康产业博览会

Yidu Tech Shines at the 9th Zhejiang International Health Industry Expo in 2023

第九届浙江国际健康产业博览会暨第二届浙江省数字健康大会在杭州举办。医渡科技CTO、首席人工智能科学家闫峻博士受邀出席“智享健康 数领未来——宁波市数字健康与未来医院实践论坛”，并分享了医疗垂域大模型的构建与应用。闫峻博士表示，公司计划推出不同参数量级的模型版本，以适配不同终端及场景的应用需求，未来会继续调优大模型各项功能。

The 9th Zhejiang International Health Industry Expo and the 2nd Zhejiang Digital Health Conference were held in Hangzhou. Dr. Yan Jun, CTO and Chief AI Scientist at Yidu Tech, was invited to the "Smart Health, Leading the Future - Ningbo City Digital Health and Future Hospital Practice Forum," sharing the construction and application of large language model in the medical vertical field. Dr. Yan revealed that Yidu Tech plans to launch models with different parameter sizes to meet the application needs of various terminals and scenarios and will continue to optimize the functionalities of the large language models in the future.



业务进展

Business Progress

医渡云承建的国家重大公共卫生事件医学中心大数据平台顺利通过终验收

Undertaken by Yidu Cloud, National Major Public Health Event Medical Center Big Data Platform Successfully Passes Final Acceptance

由华中科技大学同济医学院附属同济医院建设，医渡科技旗下医渡云承建的国家重大公共卫生事件医学中心大数据平台验收会在武汉召开。经过专家组的评审，同意该平台通过最终验收，标志着平台正式进入运行阶段。这不仅是对平台价值的高度认可，也是对医渡云平台建设能力和运营服务能力的肯定。

The acceptance meeting for the National Major Public Health Event Medical Center Big Data Platform, constructed by Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology and undertaken by Yidu Cloud, a subsidiary of Yidu Tech, was held in Wuhan. After the expert panel's review, the platform was approved for final acceptance, signifying its official entry into the operational phase. This not only represents high recognition of the platform's value but



also affirms the platform construction and operational service capabilities of Yidu Cloud.

医渡云承建的临床试验机构评价数据平台正式进入试运行阶段

**Undertaken by Yidu Cloud, Clinical Trial Institution Evaluation Data Platform
Officially Enters Trial Operation Phase**

国家药监局与中国医学科学院联合召开临床试验机构试行评价启动会，作为临床试验机构评价数据平台的建设方，医渡云凭借丰富的实践经验和先进的技术能力共同推动临床试验机构评价数据平台的建设和试运行，为我国药品监管和临床试验机构管理提供了重要的支持和保障。会议的成功召开代表着医渡科技承建的全国性平台——临床试验机构评价数据平台正式进入试运行阶段。

The National Medical Products Administration and the Chinese Academy of Medical Sciences convened a meeting to launch the trial evaluation of clinical trial institutions. As the builder of the clinical trial institution evaluation data platform, Yidu Cloud, with its rich practical experience and advanced technical capabilities, jointly promoted the construction and trial operation of the clinical trial institution evaluation data platform, providing important support and assurance for China's drug regulation and clinical trial institution management. The successful convening of the meeting signifies the trial operation of the national platform—the clinical trial institution evaluation data platform—undertaken by Yidu Tech.



医渡云中标西南地区某三甲医院科研大数据中心等采购项目

Yidu Cloud Wins Bid for a Southwestern-Region Tertiary Hospital's Procurement Projects including Scientific Research Big Data Center

医渡云将利用人工智能和大数据技术助力医院建设科研大数据中心，对临床科研数据整合汇聚、统一标准、统一管控，提供数据交互、管理、治理、服务和监管等全生命周期的大数据管理，赋能医院科研创新与学科建设的同时，辅助医院精细化管理决策更加精准、及时和科学。

Yidu Cloud will use artificial intelligence and big data technology to assist the hospital in constructing a scientific research big data center, integrating and converging clinical research data, establishing uniform standards and unified control, and providing data interaction, management, governance, services, and supervision throughout the entire big data lifecycle. This will empower the hospital's research innovation and academic construction while assisting the hospital in making more precise, timely, and scientific refined management decisions.

HLT 助力兆科眼科 TAB014 III 期临床试验的全面推进与执行

HLT Supports Zhaoke Ophthalmology's TAB014 Phase III Clinical Trial's Comprehensive Progress and Execution

兆科眼科发布公告，TAB014 的第 III 期临床试验的患者入组工作已于 2023 年 9 月 16 日提早完成。医渡科技旗下开心生活科技（HLT）为该项目提供全面服务，包括项目的落地执行、进度把控、质量交付、数字化运营、协助患者入组等，为该项目全面推进提供助力。

Zhaoke Ophthalmology announced that patient enrollment for the phase III clinical trial of TAB014 was completed ahead of schedule on September 16, 2023. Happy Life Technology (HLT), a subsidiary of Yidu Tech, provided comprehensive services for the project, including on-the-ground implementation, progress control, quality delivery, digital operations, and patient enrollment assistance, contributing to the overall advancement of the project.

HLT 中标某生物科技公司真实世界研究项目

HLT Wins Bid for a Biotech Company's Real-World Study Project

该项目是一项非干预性真实世界研究项目，旨在描述中国慢性淋巴细胞性白血病/小淋巴细胞淋巴瘤患者的治疗模式、临床结局及安全性，HLT 将为其提供真实世界研究服务，以智能技术助力研究高效开展。

The project is a non-interventional real-world study aimed at describing the treatment patterns, clinical outcomes, and safety of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in China. HLT will provide real-world research services, utilizing intelligence technology to support the efficient progression of the study.

HLT 中标某跨国药企阿尔茨海默症真实世界研究项目

HLT Wins Bid for a Multinational Pharmaceutical Company's Alzheimer's

Disease Real-World Study Project

该项目旨在描述阿尔茨海默症患者疾病特征及治疗模式,应用线上创新招募方式,与 HLT 远程智能临床试验平台 DCT 结合,打造了 HLT 数字化特色。

The project seeks to describe the disease characteristics and treatment patterns of Alzheimer's disease patients, applying innovative online recruitment methods in combination with HLT's Decentralized Clinical Trial Platform (DCT), creating a distinctive digital feature for HLT.

HLT 中标某眼科基因治疗头部企业项目

HLT Wins Bid for an Ophthalmic Gene Therapy Leading Enterprise's Project

该客户为眼科基因治疗的头部企业, HLT 将为其提供主打产品的包括医学撰写、医学监查等相关的工作, HLT 以眼科领域的高度专业性, 获得客户的认可和肯定, 将加快推进, 助力产品加速上市。

The client is a leading enterprise in ophthalmic gene therapy. HLT will provide a suite of services for its main products, including medical writing and medical monitoring. HLT's high degree of professionalism in the field of ophthalmology has been recognized and affirmed by the client, which will accelerate the project's progress and assist in the rapid market launch of the product.

HLT 中标华东地区某中医医院项目, 实现 DCT 突破应用

HLT Wins Bid for a Traditional Chinese Medicine Hospital Project in East China, Achieving DCT Application Breakthrough

HLT 将负责该中医医院中药肿瘤 DCT 助研平台项目 (I 期) 建设, 并提供临床协调服务, 助力医院肿瘤临床研究, 切实推动科技成果转化。值得注意的是, 该项目是 HLT 的远程智能临床试验平台 DCT 在数字化中医药领域的突破性应用。

HLT will be responsible for constructing the phase I of the Traditional Chinese Medicine



(TCM) Hospital's oncology DCT support platform project and providing clinical coordination services to aid the hospital's oncology clinical research and effectively promote the transformation of scientific and technological achievements. Notably, this project represents a breakthrough application of HLT's Decentralized Clinical Trial Platform (DCT) in the digital TCM field.

因数云主运营的“江苏医惠保1号”参保人数超470万人，“北京普惠健康保”突破350万人

CausaCloud, the Main Operator of "Jiangsu Hui Min Bao No.1" with Over 4.7 Million Insured and "Beijing Supplementary Insurance" Surpassing 3.5 Million Insured

截至12月31日，2024年度“江苏医惠保1号”参保人数突破470万人，2024年度“北京普惠健康保”参保人数突破350万人。医渡科技旗下因数云已连续三年担任“江苏医惠保1号”和“北京普惠健康保”的主运营平台。截至目前，医渡科技已中标并参与4省12市“惠民保”项目，通过技术优势推动惠民保项目在全国落地。

As of December 31, 2024, the number of insured for "Jiangsu Hui Min Bao No.1" for the year 2024 has exceeded 4.7 million, and the number of insured for "Beijing Supplementary Insurance" has surpassed 3.5 million. Yidu Tech's subsidiary CausaCloud has been the main operating platform for both "Jiangsu Hui Min Bao No.1" and "Beijing Supplementary Insurance" for three consecutive years. To date, Yidu Tech has won bids and participated in the "Hui Min Bao" projects in 12 cities across 4 provinces, using its technological advantage to promote the implementation of supplementary insurance projects nationwide.

集团荣誉

Honors of Yidu Tech

医渡科技获评“2023 年度卓越人工智能企业”

Yidu Tech Awarded "Outstanding Artificial Intelligence Enterprise of 2023"

由中国科学院《互联网周刊》、中国社会科学院信息化研究中心、eNet 研究院、德本咨询联合主办的 2023 (第二十一届) 中国互联网经济论坛在京举办。会上，备受瞩目的“金 i 奖”揭晓。医渡科技凭借突出的人工智能技术实力，以及在医疗垂直领域大语言模型研发与应用等丰富的实践成果，获评“2023 年度卓越人工智能企业”。

At the "2023 (21st) China Internet Economy Forum" co-hosted by the Chinese Academy of Sciences' "China Internet Week," the China Informationization Research Center of Social Sciences (CIS), eNet Research Institute, and Deben Consulting (DBC), the prestigious "Golden I Award" was announced. Yidu Tech, with its outstanding artificial intelligence technology strength and rich practical achievements in the development and application of large language model in the medical vertical field, was named "Outstanding Artificial Intelligence Enterprise of 2023."



医渡科技荣登 2023 年中国创新力量 50 榜单

Yidu Tech Named to China's Top 50 Innovators List of 2023

极客公园发布了 2023 年度「中国创新力量 50 榜单 (InnoForce 50)」，入选的皆是在过去一年为泛计算机科学领域及其交叉领域带来创新和突破的中国公司/机构。医



渡科技凭借强劲的技术实力和出色的创新能力，成为人工智能赛道唯一入选的医疗智能企业，与华为、阿里云、百度智能云等人工智能企业一同上榜。

GeekPark released the "InnoForce 50" for 2023, featuring Chinese companies/organizations that have brought innovation and breakthroughs to the broader computer science field and its interdisciplinary areas over the past year. With its robust technical strength and excellent innovative capabilities, Yidu Tech has been the only healthcare intelligence enterprise in the field of artificial intelligence to make the list, joining other AI enterprises such as Huawei, Alibaba Cloud, and Baidu AI Cloud.



上图为榜单节选

医渡科技获评“2023 年度卓越数字创新企业”与“卓越医疗服务创新企业”

Yidu Tech Honored with "Outstanding Digital Innovation Enterprise of 2023" and "Outstanding Medical Service Innovation Enterprise of 2023"

凭借在医疗大模型研发与应用领域的创新探索，医渡科技近日荣获知名财经媒体《经济观察报》颁发的“2023 年度卓越数字创新企业”与“2023 年度卓越医疗服务创新企业”。

With innovative explorations in the development and application of large language model in the medical vertical field, Yidu Tech has recently been awarded "Outstanding Digital Innovation Enterprise of 2023" and "Outstanding Medical Service Innovation Enterprise of 2023" by the renowned financial media "The Economic Observer".



医渡科技入选“CHS 2023 中国大健康产业榜”4项榜单

Yidu Tech Selected for Four Categories on the "CHS 2023 China Big Health Industry List"

亿欧大健康揭晓“CHS 2023 中国大健康产业榜”系列榜单，医渡科技凭借在医疗智能领域的领先地位，以及在医疗大模型研发、惠民保运营等领域的创新探索，一举登上“2023 中国医疗健康产业创新榜”和“2023 中国数字医疗产业活力榜”，并强势入选其中4项榜单，包括医渡科技 CEO、联合创始人徐济铭荣获“2023 年中国大健康产业创新人物”；医渡科技荣获“2023 年中国医疗健康大模型创新企业 TOP10”；医渡科技荣获“2023 年中国 AI 医疗企业 TOP20”和医渡科技旗下因数云荣获“2023 年多元支付企业 TOP10”。

EqualOcean Big Health unveiled the "CHS 2023 China Big Health Industry List" series, and Yidu Tech, with its leading position in the medical intelligence field and innovative explorations in the development of large language models in the medical vertical field and the operation of supplementary insurance, has topped the "2023 China Medical and Health Industry Innovation List" and "2023 China Digital Medical Industry Vitality List." Yidu Tech strongly entered four categories, including CEO and Co-founder Xu Jiming being honored as "2023 China Big Health Industry Innovative Figure"; Yidu Tech



as "2023 China Medical and Health Large Language Model Innovation Enterprise TOP10"; Yidu Tech as "2023 China AI Medical Enterprise TOP20"; and Yidu Tech's subsidiary CausaCloud as "2023 Diversified Payment Enterprise TOP10."

医渡科技糖尿病数字疗法案例荣登“数字中国创新应用建设案例 100”榜首

Yidu Tech's Diabetes Digital Therapeutic Case Tops the List of "Digital China Innovation Application Construction Case 100"

凭借创新能力及专业实力，医渡科技糖尿病数字疗法创新解决方案入选海南省“2+3”健康服务包项目，并于今年 10 月在海南陵水开展试点，这标志着国内首个省级糖尿病数字疗法项目的正式落地。该案例也荣登《互联网周刊》“2023 年度数字中国创新应用建设案例 100”榜单首位。

With its innovative capabilities and professional strength, Yidu Tech's diabetes digital therapeutic innovative solution was selected for the Hainan Province "2+3" Health Service Package project and launched a pilot in Hainan Lingshui this October, marking the official launch of the country's first provincial-level diabetes digital therapeutic project. The case also topped the "China Internet Week's 2023 Digital China Innovation Application Construction Case 100" list.

2023年度数字中国创新应用建设案例100 (1-50)			
序号	使用方	提供方	案例名称
1	海南省卫生健康委员会	医渡科技	医渡科技糖尿病数字疗法创新解决方案落地海南陵水

节选自“2023 年度数字中国创新应用建设案例 100”榜单

投资者交流

Investor Communication

华金证券维持医渡科技“买入”评级

Huajin Securities Maintains "Buy" Rating for Yidu Tech

华金证券发研报指出，医渡科技自研医疗垂域大模型，与华为强强联合，将持续推动医疗大模型的创新与应用，加速医疗健康产业的智能化转型升级，维持医渡科技“买入”评级。

Huajin Securities' research report states that Yidu Tech's proprietary large language model in the medical vertical field, in strong alliance with Huawei, will continue to drive the innovation and application of medical large language models, and accelerate the intelligence transformation and upgrading of the medical and health industry, maintaining a "Buy" rating for Yidu Tech.

中泰证券发布研报推荐关注医渡科技

Zhongtai Securities Releases Research Report Recommending Attention to Yidu Tech

中泰证券发布的研报中指出，人工智能新一轮十年级的技术和产业革命大幕已经拉开，国内大模型仍处于群雄逐鹿、快速迭代阶段，未来空间大且会格局收敛，应用端长期空间最大，厂商百花齐放。在医疗场景应用，中泰证券建议关注医渡科技。

Zhongtai Securities' research report indicates that a new decade-long wave of technology and industrial revolution in artificial intelligence has begun. Domestic LLMs are still in a stage of intense competition and rapid iteration, with significant future potential and an expected convergence of industry structure. The application side has the largest long-term potential, with diverse players flourishing. In medical scenario applications, Zhongtai Securities suggests paying attention to Yidu Tech.